|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
Oncology: EMEA Approval Lags
Author(s)Kevin Gopal
London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.
Advertisement
Articles in this issue
over 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
PBMs: Merck-Medco in the Hot Seatover 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
A Five-Year Forecast: Clear Seas Ahead?over 24 years ago
Weak Bones, Strong Marketover 24 years ago
Approvals: Novartis’ Silver Liningover 24 years ago
Pfizer and others Pitch Inover 24 years ago
Illegal Sales in Indiaover 24 years ago
Health Plan Premiums: Pharma Takes the Blameover 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
4
Pharmaceutical Executive Daily: FDA Approves Breztri
5